Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Luznik, Leo  [Clear All Filters]
2014
Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014.
2016
McDonald-Hyman C, Flynn R, Panoskaltsis-Mortari A, Peterson N, MacDonald KPA, Hill GR, Luznik L, Serody JS, Murphy WJ, Maillard I, et al. Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5 dependent manner. Blood. 2016.
2019
McCurdy SR, Luznik L. How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. Blood. 2019;134(21):1802-1810.
Radojcic V, Luznik L. Mechanism of action of posttransplantation cyclophosphamide: more than meets the eye. J Clin Invest. 2019;130.
Imus PH, Blackford AL, Bettinotti M, Luznik L, Fuchs EJ, Huff CAnn, Gladstone DE, Ambinder RF, Borrello IM, Fuchs RJ, et al. Severe cytokine release syndrome after haploidentical peripheral blood transplantation. Biol Blood Marrow Transplant. 2019.
2020
DeZern AE, Zahurak ML, Symons HJ, Cooke KR, Rosner GL, Gladstone DE, Huff CAnn, Swinnen LJ, Imus P, Borrello I, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4(8):1770-1779.
2021
Sterling CH, Tsai H-L, Holdhoff M, Bolaños-Meade J, Luznik L, Fuchs EJ, Huff CAnn, Gocke CB, Ali SAbbas, Borrello IM, et al. "Allogeneic blood or marrow transplant with non-myeloablative conditioning and high dose cyclophosphamide-based graft-versus-host disease prophylaxis for secondary central nervous system lymphoma". Transplant Cell Ther. 2021.
Rappazzo KC, Zahurak M, Bettinotti M, Ali SAbbas, Ambinder AJ, Bolaños-Meade J, Borrello I, DeZern AE, Gladstone D, Gocke C, et al. Nonmyeloablative, HLA-mismatched unrelated peripheral blood transplantation with high-dose posttransplantation cyclophosphamide. Transplant Cell Ther. 2021.
Tschernia NP, Kumar V, Moore DT, Vincent BG, Coombs CC, Van Deventer H, Foster MC, DeZern AE, Luznik L, Riches ML, et al. Safety and efficacy of pembrolizumab prior to allogeneic stem cell transplant in Acute Myeloid Leukemia. Transplant Cell Ther. 2021.
2022
Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, et al. BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022.
Buxbaum NProkopenko, Socié G, Hill GR, MacDonald KPa, Tkachev V, Teshima T, Lee SJ, Ritz J, Sarantopoulos S, Luznik L, et al. Chronic GvHD NIH Consensus Project Biology Task Force: Evolving path to personalized treatment of chronic GvHD. Blood Adv. 2022.
Ktena YP, Koldobskiy MA, Barbato MI, Fu H-H, Luznik L, Llosa NJ, Haile A, Klein OR, Liu C, Gamper CJ, et al. Donor T-cell DNMT3a regulates alloreactivity in murine models of hematopoietic stem cell transplantation. J Clin Invest. 2022.
Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau T-O, Mukhopadhyay R, Dickins B, Altmann H, Kramer M, Knaus HA, et al. Signatures of immune dysfunction predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J Clin Invest. 2022.
2024
Dong H, He X, Zhang L, Chen W, Lin Y-C, Liu S-B, Wang H, Nguyen LXuan Truon, Li M, Zhu Y, et al. Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nat Cancer. 2024.